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Background. Multiple myeloma is overall the 14th most common malignancy but is rarely seen in those younger than 35 years.
Those in the younger age group have been shown to have a more aggressive course but reportedly have had similar responses to
treatment compared to older cohorts. Extramedullary plasmacytomas are discrete soft tissue masses of neoplastic monoclonal
plasma cells that often occur in patients with multiple myeloma. Case. This case entails a young female with new diagnosis of
multiple myeloma and multiple extramedullary plasmacytomas presenting with neurological symptoms. She was treated with
CyBorD regimen but was refractory and progressed. Treatment was changed to DCEP regimen, and daratumumab was added for
primary refractory myeloma. The patient improved rapidly. Conclusion. This is a unique case of multiple myeloma in a young
female that had failed ﬁrst-line treatment but responded to targeted therapy of daratumumab. It highlights that multiple myeloma
may present atypically in young patients. More research is needed on appropriate initial diagnosis and treatment of patients in this
age group.

1. Introduction
Multiple myeloma is a malignant B-cell disorder that leads to
proliferative plasma cells. It is the 14th most common malignancy accounting for 1.8% of all malignancies and 10% of
hematologic malignancies [1]. However, multiple myeloma
rarely occurs in those younger than 35 years (0.5%) [1]. Prior
studies have shown a more aggressive presentation in this
age group with higher rates of extramedullary plasmacytomas, plasma cell leukemias (11%), osteolytic lesions, renal
failure (25%), and Bence Jones proteinuria (81%) [2–10].
This could be explained by either a delay in diagnosis or the

inherent aggressive nature of disease in younger patients
[11]. It has also been reported that this younger age group
has had similar overall survival and remission to older
cohorts [2–5, 11].
Here, we present a case of a young female newly diagnosed with multiple myeloma. She initially presented with
signiﬁcant neurological symptoms and multiple extramedullary plasmacytomas throughout the body including
intracranially. She received ﬁrst-line treatment with combined conventional chemotherapy and proteasome inhibitor
(bortezomib), but was refractory. Second-line intensive
chemotherapy initially failed, but with the addition of single
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agent daratumumab, the patient had a favorable disease
response.

2. Case
A 24-year-old Egyptian female presents after a syncopal fall
and head trauma. She reports having multiple falls for the
past month prior to admission. Upon evaluation, the patient
reported neurological symptoms including left-sided
weakness in the upper and lower extremities, diplopia, and
ataxia along with dysphagia. Most pertinent neurological
exam ﬁndings were left abducens (CN VI) palsy, bilateral
upper and lower extremity weakness of 2/5, and inability to
stand due to pain with a 1 cm palpable left soft tissue pelvic
mass.
Initial lab work revealed an elevated lactate dehydrogenase 375 U/L. The CBC and CMP ﬁndings were otherwise
normal. Previous imaging from Egypt showed a fracture of
her mandible with bilateral plate placement on X-ray. On
our imaging, CT brain and maxillofacial showed several soft
tissue masses present with contiguous bony erosion and
destruction involving the central skull base and mandible
(Figure 1(a)). At the skull base, the soft tissue mass eroded
the basisphenoid and bordering maxilla, as well as the left
greater wing of the sphenoid into the middle cranial fossa
with inﬁltration of the left lateral rectus in the left orbit. CT
of the spine showed paraspinal and epidural masses with
bordering vertebral erosion (Figure 2(a)). CT of the chest,
abdomen, and pelvis with contrast showed multiple lesions,
with soft tissue inﬁltrating the chest wall, and left hemipelvis
straddling the sacrum to involve the left gluteus musculature. These were superimposed on diﬀusely lytic lesions
throughout thoracolumbar spine, some associated with mild
compression fractures. MRI of the brain, cervical, thoracic,
and sacral spine showed decreased T1 and T2 along with
hyperintensive signals on diﬀusion of the calvarium, skull
base, and facial bones with lytic lesions. Large expansile
lesion involves L lateral orbital bony margin and zygoma
11 mm × 5 mm × 1.2 cm concerning for neoplasm. No new
ischemic changes were observed in the brain. Cervical spine
shows irregular T1 enhancement in clivus, C1, and C2,
diﬀusely throughout C3-T1, and there was no central canal
or foraminal compromise. Thoracic spine with extensive
metastatic lesions with multiple compressions most pronounced at T4, T6, T8, and T11 and leptomeningeal involvement. Lumbar spine showing compression upon the
cauda equina at the levels of L3-L4 and L4-L5 soft tissue in
the left L3-L4, L4-L5, and L5-S1 neural foramina, encasing/
compressing the left L3, L4, and L5 nerve root and bulky
bilateral sacral masses.
At the time of initial evaluation, the main diﬀerential
diagnosis was metastatic solid tumor malignancy, atypical
neuroblastomas, and lymphoma. Decadron 4 mg every 6
hours was given for empiric treatment to reduce paraspinal
inﬂammation. A ﬁne needle aspiration/biopsy was done via
CT guidance of a soft tissue sternal mass.
Flow cytometry on the biopsied specimen revealed an
immunophenotype of monotypic plasma cells (11% of cells)
positive for cytoplasmic lambda, CD38, CD56, dim CD45,
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and CD117 and negative for CD19 and CD20 with morphology showing atypical plasma cells with high nucleus-tocytoplasm ratio, eccentric and irregular nucleuses, and
frequent mitosis (Figures 3 and 4). Cytopathology immunohistochemical (CD20, CD117, cyclinD1, c-MYC, and p53)
and in situ hybridization (EBR) stains showed neoplastic
cells positive for c-MYC, CD56 and CD117 and negative for
CD19, CD 20, cyclinD1, p53, and EBER. FISH using probe
and location MYC (8q24) was negative for MYC rearrangement. A full multiple myeloma workup was then
pursued. Serum free light chain analysis showed kappa light
chain of 0.04 mg/dL, lambda light chain of 213 mg/dL, high
IgG levels of 1840 mg/dL with an IgG lambda monoclonal
band on urine and serum immunoﬁxation, and low beta-2
microglobulin 0.5 mg/L.
According to the 2016 International Myeloma Working
Group criteria, this patient met criteria for multiple myeloma with a biopsy proving soft tissue extramedullary
plasmacytoma and multiple myeloma deﬁning events with
osteolytic lesions shown on imaging and a free light lambda
chain ratio >100 mg/L and elevated LDH. The patient was
diagnosed with stage III plasma cell IgG lambda multiple
myeloma [12, 13]. The patient clinically had acute disease
progression and severely worsening neurological symptoms;
a bone marrow biopsy was deferred. A lumbar puncture was
done and showed no malignant plasma cells in the CSF. She
received palliative radiation therapy to the skull base, thoracic spine, and sacrum, and systemic treatment was started.
Cyclophosphamide 600 mg/m2, bortezomib 1.3 mg/m2,
and dexamethasone 40 mg (CyBorD) regimen was initially
given [14, 15]. An attenuated dose of cyclophosphamide was
used with an attempt to quickly debulk the disease. Unfortunately, the disease continued to progress, the patient
had worsening jaw pain, within 18 days after starting
CyBorD. Repeat CT of the maxillofacial area revealed enlargement of the left masticator space lesion. Her treatment
regimen was changed to second-line therapy with dexamethasone 40 mg, cyclophosphamide 400 mg/m2, etoposide
40 mg/m2, and cisplatin 10 mg/m2(DCEP) [16]. Seven days
later, with symptoms of dysphagia and lower extremity
weakness, the decision was made to add daratumumab
16 mg/kg for primary refractory myeloma [17, 18].
After addition of daratumumab, she began to clinically
improve. Subsequent CT of the maxillofacial showed a decrease in previously seen masticator space masses
(Figure 1(b)). Furthermore, there were decreased size paraspinal and epidural lesions on CT lumbar and thoracic
spine (Figure 2(b)). The Chest, abdomen, and pelvis CT scan
also demonstrated substantial interval decreased size of right
chest wall and left hemisacrum soft tissue masses. Based on
the International Myeloma Workshop Group criteria [19],
the patient had a partial response to one dose of daratumumab, with CT imaging showing ≥50% reduction in
size of soft tissue plasmacytoma and marked reduction in
lambda light chain levels from 213 to 3.02 mg/dL. The main
toxicity during the hospital course was neutropenia with
fever and a nadir ANC 500. Moreover, repeat MRI brain and
spine 17 days later signiﬁcantly decrease in enhancing soft
tissue in the lumbar extradural space, with the resolution of
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(a)

(b)

Figure 1: Soft tissue masses of the left masticator space seen on admission is associated with adjacent mandibular erosion (a). This
progressed and increased in size during admission, but ﬁnally showed response on CDEP and daratumumab (b).

(a)

(b)

Figure 2: Admission imaging (a) revealed multiple paraspinal and epidural masses (arrows) which decreased (b) following DCEP and
daratumumab.

compression upon the cauda equina at the levels of L3-L4
and L4-L5 as described above. Persistent soft tissue in the left
L3-L4, L4-L5, and L5-S1 neural foramina, encasing/compressing the left L3, L4, and L5 nerve roots was found. Slight
improvement of large bulky bilateral sacral masses was
observed, which extends to the left presacral and left sciatic
foramen regions. Persistent obliteration of the left sacral
foramina was observed. Stable mild superior endplate

pathologic compression deformities at T12, L4 and L5 were
also observed. In the brain MRI, the bony lesions overall
appears smaller in size and less bulky, most consistent with a
favorable response to treatment. No evidence for brain
parenchymal metastatic disease, acute infarct, or acute
hemorrhage. A repeat ﬂow cytometry was done 30 days into
her admission of her left iliac, but cytopathology analysis was
done and showed from the core biopsy with paucicellular
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Figure 3: H&E (haematoxylin and eosin) stain of the biopsied soft tissue sternal mass shows soft tissue is diﬀusely inﬁltrated by large sheets
of large cells with plasmacytoid morphology.
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Figure 4: Flow cytometric analysis reveals a plasma cell population (P4) with higher side scatter (SSC). The plasma cells are positive for
CD38bright, cytoplasmic lambda, and CD56 and negative for CD 19.

and a few plasma cells and rare plasmacytoid cells of uncertain lineage (erythroid versus plasma cellular), amidst
scattered bone marrow elements, ﬁbrous tissue, and
abundant blood. Immunostains were performed and show
rare CD138 staining plasma cells, abundant CD3 staining
T cells. Kappa and lambda are noncontributory due to
depletion of the tissue upon deeper sectioning. Cam 5.2 is
negative and excludes any epithelial cells. She continued to
improve, and her ANC rose above 1000 over the next few
days. She began moving her lower extremities and was able
to walk with crutches at the time of discharge.

3. Discussion
This is a rare case of a very young patient presenting with
neurological symptoms found to have multiple myeloma

associated with multiple soft tissue extramedullary plasmacytomas. This case has multiple atypical aspects including
the patient’s age, presenting symptoms, and number and
locations of extramedullary plasmacytomas. The median age
of diagnosis of multiple myeloma is 69 years with only 15%
of cases occurring in those less than 55 years [1]. Multiple
myeloma occurs slightly more in men with typical symptoms
of fatigue, anemia, bone pains, and/or hypercalcemia with
renal insuﬃciency (CRAB features). The neurological
complications, usually radiculopathy and peripheral neuropathies, are associated with spinal cord compression or
neural compression secondary to bone damage.
The patient in this case however presented with atypical
neurologic ﬁndings often seen in CNS disease. She had
diplopia and ataxia along with paraplegia. The location of
her plasmacytomas resulted in these unusual neurologic
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ﬁndings. In addition, given her high disease burden, her labs
were not consistent with the typical CRAB features, and in
fact the beta-2 microglobulin was low. Her IgG serum level
was mildly elevated. The bulk of her measurable disease in
the serum was noticed by the elevated serum lambda light
chain of 213 mg/dL. Given the extent of bone damage, she
had an oligosecretory myeloma, which is rare.
Another unique presentation of this case is the large
number of soft tissue extramedullary plasmacytomas.
Extramedullary plasmacytomas have an incidence of 0.04
cases per 100,000 individuals and usually are solitary masses
with 80–90% arising from mucosal associated lymphoid
tissue in the upper airways including nasopharynx and
paranasal sinuses [20]. Furthermore, only 1-2% of patients at
the time of initial diagnosis have extramedullary disease, and
8% develop extramedullary disease later on [21]. They also
commonly present with obstruction of the nasal passages,
masses in the palatal or maxillary, and with erosions leading
to epistaxis and facial pain [20–22]. In this patient, she had
multiple soft tissue masses throughout her chest wall, left
pelvis, and thoracic spine along with a skull-base mass with
intracranial and intraorbital extension. There have been only
a few case reports of intracranial involvement with either
multiple myeloma or intracranial plasmacytomas, but this
level of intracranial involvement and associated chest and
abdominopelvic involvement in one patient has not been
reported in the literature [21–25]. The clinical scenario is
suggestive of a possible aggressive form of oligosecretory
myeloma which mainly progresses as plasmacytomas
throughout the body, with minimal measurable disease
present in the serum.
Despite progress in eﬀective treatment, multiple myeloma remains incurable. The patient not only failed to respond to initial treatment with CyBorD regimen but also she
progressed acutely while on therapy. Second-line therapy
with DCEP regimen was ineﬀective acutely until daratumumab was added on and then she had a notable
response.
The eﬃcacy of daratumumab in treatment of multiple
myeloma has been well documented over the past decade.
Daratumumab is a monoclonal antibody to CD38 and
widely expressed by several hematopoietic cells in the bone
marrow, most notably plasma cells. Of note, it is also
expressed on osteoclasts and bronchial epithelial cells [26]. It
has been shown in preclinical studies that daratumumab
kills myeloma cells by both antibody-dependent cellular
cytotoxicity and phagocytosis by blocking the inhibitory
signals from CD38, thus boosting cytotoxic T cells [27–29].
In its ﬁrst clinical trial, SIRIUS, daratumumab was used in
relapsed refractory myeloma in a multicentered phase 2 trial.
A majority of these patients (80%) had received autologous
stem-cell transplants and were refractory to proteasome
inhibitors and immunomodulatory drugs (95%) and received a median of ﬁve previous lines of therapy. The 12month overall survival was 64.8%, and median overall
survival with 17.5 months was 29.2% showing overall response with 30% of the patients responding to daratumumab
[18]. In 2015, it was initially approved by the FDA for
treatment of patients with refractory multiple myeloma who
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had failed 3 or more prior lines of therapy [30]. In the
CASTOR and POLLUX trial, both phase 3, randomized,
multicenter, open label trials involving adding daratumumab for relapsed or refractory patients (who had
already received one or more previous lines of therapy
(autologous stem-cell transplant (ASCT), alkylating agents
and proteasome inhibitors). Both trials showed signiﬁcantly
increased response rates and progression-free survival by
more than 60% with the addition of daratumumab [31, 32].
Since then, daratumumab has been approved, in combination with proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) in the upfront setting for newly
diagnosed myeloma patients. These clinical trials have
shown daratumumab to work synergistically with IMiDs
and PIs with high potency and eﬃcacy in killing myeloma
cells with tolerable toxicity proﬁles [26, 31–36].
The ALCYONE trial was the ﬁrst phase 3 daratumumab
clinical trial to gain FDA approval for newly diagnosed
multiple myeloma patients who were ineligible for autologous stem-cell transplantation. The patients were randomized to either nine cycles of bortezomib, melphalan, and
prednisone alone (control arm) or with daratumumab
(experimental arm) until disease progression. Patients in the
daratumumab group had signiﬁcantly longer progressionfree survival at 18 months at 71.6% vs. 50.2% in the control
group. The overall response in the daratumumab group was
91% with 22.3% negative for minimal residual disease
(MRD) compared to 74% overall response and 6.2% negative
for MRD in the control group [33]. MRD was deﬁned by 1
tumor cell per 105 white cells.
Finally, the MAIA trial was done by comparing either
daratumumab and lenalidomide with dexamethasone or
lenalidomide with dexamethasone in multiple myeloma
patients who were ineligible for autologous stem-cell
transplant. Those in the daratumumab group had disease
progression/death in 26.4% compared to 38.8% with lenalidomide and dexamethasone arm. Patients with daratumumab had 30 months without disease progression and
were alive 70.6% in the experimental arm compared to 55.6%
to the control arm [34]. A complete response or better was
achieved in 47.6% of patients in the daratumumab group
compared to 24.9% in the control group. In terms of MRD,
24.2% of patients in the daratumumab arm compared to
7.3% in the control arm had evidence of minimal residual
disease [34]. Throughout all these trials the most common
manageable toxicities of daratumumab were neutropenia,
thrombocytopenia, increased respiratory infections, and
infusion-related reactions.
Based on these clinical trials, daratumumab is highly
potent and eﬀective in the treatment of myeloma patients in
combination with PIs and IMiDs, but for the advanced
myeloma patient with high disease burden such as our
patient, often the initial therapy for rapid disease control
remains combination therapies such as CyBorD, DCEP, or
other such heavy chemotherapy-based regimen. In this case,
the availability of PIs and IMIDs was limited due to the
inpatient setting. Additionally, at the time of the actual
events, daratumumab was only FDA approved in the relapsed refractory multiple myeloma. Therefore, the choice
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for use of CyBorD induction with escalation to DCEP and
daratumumab added once deemed refractory. This case
suggests that not only would daratumumab be option for
upfront therapy with PIs/IMiD combinations but also with
multidrug chemotherapy regimens such as DCEP.
This case report shows a unique regimen of DCEP plus
daratumumab resulting in a robust initial response, after the
failure of CyBorD. This case report suggests that daratumumab in combination with DCEP may be another
option to use for inpatient treatment of primary refractory
and aggressive multiple myeloma disease. Especially, given
the real world delays in obtaining IMiD/PI therapy for
acutely ill hospitalized patients, this case also highlights how
very diﬀerent the presentation of multiple myeloma may be
in a very young patient compared with older patients.

4. Conclusion
This provides insight into not only how young patients may
present aggressively but also a potential way to manage it.
The risk of multiple myeloma increases with age, but this is a
case report of a patient who was diagnosed with a large
amount of disease burden at a young age showing that young
patients may present more aggressively. This case highlights
that multiple myeloma should be included in the diﬀerential
diagnosis of a young patient with neurological symptoms
and mass lesions, after more common causes have been
ruled out. Moreover, this patient has an aggressive form of
multiple myeloma presenting with several plasmacytomas
and neurological symptoms. She progressed and failed induction with CyBorD, and only after switching to DCEP
with addition of daratumumab, did she have a partial response. The response was long enough to stabilize and
discharge her from the hospital safely.
Further research is needed in this ﬁeld to determine
optimal treatment regimens for this subset of young patients.
These cases are rare, thus hampering the use of clinical trials
in these patients. Therefore, case reports and registries may
be needed to help collect data for future analysis and studies.
Ideally these patients would be most likely to beneﬁt from a
cure, given the young age and potential loss of life years.

Additional Points
Clinical Signiﬁcance. It is important to recognize that
multiple myeloma can occur in very young patients and may
present and respond diﬀerently in this younger-aged cohort.
Diagnosing and treating this group can be challenging, and it
is crucial to identify optimal initial treatment regimens for
these patients. A great way to gather this information would
be by creating a registry.
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